EGFR and ovarian cancer: IL-6 also activates the EGFR/AKT/NF-κB and EGFR/MEK/NF-κB signaling pathways to induce the expression of apoptosis suppressor proteins, including BCL-2, BCL-XL, and X-linked apoptosis suppressor protein (XIAP), thus inducing resistance to tocilizumab in combination with platinum in ovarian cancer cells [102].